LZLi-Hua Zhao

Li-Hua Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Li-Hua Zhao has a total of 124 co-authors. Here are the top co-authors by number of shared publications:

  • H. Eric Xu

    CAS Key Laboratory of Receptor Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

    28 shared publications
  • Wen Hu

    State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

    12 shared publications
  • Qingning Yuan

    Research Center for Medicinal Structural Biology, National Research Center for Translational Medicine • Shanghai, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

    11 shared publications
  • Dehua Yang

    University of Chinese Academy of Sciences, Beijing, China

    10 shared publications
  • Qian He

    State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

    10 shared publications
  • Ming-Wei Wang

    Research Center for Medicinal Structural Biology, National Research Center for Translational Medicine at Shanghai, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    9 shared publications

Latest Publications

  • Open Access

    β-arrestin1 directly engages Gαs to sustain endosomal GPCR signaling

    by Qian He, Qingning Yuan, Xinheng He, Wen Hu, H. Eric Xu, Li-Hua Zhao

    β-arrestins (βarrs) are canonical terminators of G protein–coupled receptor (GPCR) signaling, yet internalized receptors paradoxically sustain βarr-dependent G s /cAMP signaling from endosomes. How a desensitizing scaffold can instead promote G protein activation has remained unresolved, because the receptor–βarr–G protein assemblies described so far position the two transducers on opposite faces of the receptor, with no contact between them. Using the parathyroid hormone type 1 receptor (PTH1R), we show that βarr1 binds Gα s directly, engages its nucleotide-free state, and does so far more strongly than it engages Gβγ. A cryo-EM structure of the agonist-bound PTH1R– βarr1–Gα s complex at ∼3.1 Å resolution reveals how: βarr1 anchors to the phosphorylated receptor C-tail, leaving the transmembrane core free for Gα s , and reorients to build a direct, three-node interface in which its finger, C- and back loops clamp the Switch I, Switch II and α3/β5 regions of Gα s . Disrupting either side of this interface abolishes complex assembly and selectively collapses the internalization-dependent phase of cAMP production, and the same interface governs βarr1–Gα s coupling at the glucagon-like peptide-1 receptor. β-arrestin1 therefore acts as a positive regulator that holds Gα s in a signaling-competent state, providing a unifying structural basis for sustained endosomal GPCR signaling.


  • Structural basis of β-arrestin coupling and transducer selectivity in PAC1R

    by Min Zhang, Xin Li, Qing-Ning Yuan, Wen Hu, H. Eric Xu, Li-Hua Zhao

    The pituitary adenylate cyclase-activating polypeptide receptor (PAC1R) is a class B G protein–coupled receptor (GPCR) that engages both G proteins and β-arrestins to mediate diverse signaling responses, yet how PAC1R adopts distinct intracellular conformations to achieve this transducer selectivity remains poorly understood. Here, we report the cryo-electron microscopy structure of PAC1R in complex with β-arrestin 1 (βarr1), revealing a core-engaged conformation. Comparison with the Gs-bound PAC1R structure shows that βarr1 engagement is associated with remodeling of the intracellular transmembrane bundle, including TM5 reorientation and inward movement of TM6, resulting in a receptor core geometry distinct from that of the G protein–bound state. Comparison with the βarr1–bound parathyroid hormone receptor 1 (PTH1R) structure further reveals both conserved and receptor-specific features of βarr1 engagement. Although outward displacement of the TM5 cytoplasmic end is observed in both PAC1R–βarr1 and PTH1R–βarr1 complexes, its specific direction and the resulting TM5–TM6 rearrangements differ between receptors, correlating with distinct βarr1 finger loop orientations within the receptor core. Together, these findings suggest that β-arrestin core engagement by class B GPCRs is accompanied by receptor-specific intracellular remodeling that may contribute to transducer selectivity in PAC1R.

  • Open Access

    Arrestins as programmable integrators of GPCR signaling: structural microstates, spatiotemporal logic, and therapeutic control

    by Qian He, Li-Hua Zhao, H. Eric Xu

    Arrestins were originally defined as terminators of G protein-coupled receptor (GPCR) signaling, yet structural and mechanistic advances now reveal them as programmable, spatiotemporal integrators of cellular signaling. Recent cryo-electron microscopy studies have revealed a diverse spectrum of GPCR–arrestin engagement modes, including core-, tail-, loop-, side-engaged, and membrane-anchored conformations, across GPCR classes and arrestin isoforms. These structures reveal that arrestin recruitment operates as a conditional, allosterically regulated process rather than a binary on–off switch. The selection of the arrestin microstate is governed by layered regulatory inputs, including GPCR kinase-dependent phosphorylation barcodes, membrane and lipid cofactors, and isoform-specific mechanics, which together define the signaling geometry, duration, and subcellular localization. This structural logic provides a mechanistic foundation for biased signaling, noncanonical endosomal signaling, and GPCR-independent arrestin functions. Importantly, emerging therapeutic strategies, including intracellular allosteric modulators and molecular glues, demonstrate that arrestin signaling can be reprogrammed by directly sculpting transducer assemblies rather than ligand efficacy alone. Here, we synthesize recent structural, biochemical, and physiological insights to outline how arrestins decode regulatory inputs into signaling outcomes and how this knowledge enables the development of next-generation, structure-guided GPCR therapeutics.


  • Open Access

    N-terminally modified GLP1R agonists drive G protein bias via extracellular loop 3 displacement

    by Li-Hua Zhao, Qian He, Qingning Yuan, Guan-Guan Zhao, Gai-Hong Wang, Hua-Ling Pan, H. Eric Xu


  • Open Access

    Structural basis for lysophosphatidic acid recognition and atypical Gα q coupling by LPAR5

    by Xin Li, Kai Wang, Zhongliang Xing, Min Zhang, Wen Hu, Qingning Yuan, H. Eric Xu, Li-Hua Zhao

    Lysophosphatidic acid receptor 5 (LPAR5) is a non-endothelial differentiation gene class A G protein–coupled receptor that regulates neuropathic pain, itch, and cancer progression through coupling to G proteins. Here, we report the cryo-EM structure of LPAR5 bound to 1-oleoyl-lysophosphatidic acid (LPA) in complex with G q at 2.96 Å resolution, revealing a distinct mode of receptor activation and G protein coupling. The phosphate headgroup of LPA forms extensive polar interactions with residues from extracellular loop 2 and transmembrane helices TM5–TM7, while the lipid tail inserts into a deep hydrophobic cavity formed by TM3–TM5. Site-directed mutagenesis confirms the functional importance of these interactions. Remarkably, LPAR5 exhibits a noncanonical G protein coupling mode. Unlike previously reported GPCR–G protein structures in which the Gα C-terminal α5 helix (“wavy hook”) primarily engages TM6, the wavy hook in LPAR5 is positioned toward the intracellular loop 1–helix 8 interface. This configuration is associated with limited TM6 outward displacement and modest rearrangement at the toggle-switch position (6.48). The resulting interface is stabilized by receptor-specific interactions and supported by functional data. Together, these findings reveal an alternative mode of GPCR–G protein coupling and highlight the structural plasticity underlying signaling specificity in LPA receptors.

  • Top Cited Papers

    Structural basis of PTH1R–β-arrestin core engagement reveals design principles for G-protein-biased therapeutics

    by Li-Hua Zhao, Qian He, Qingning Yuan, Min Zhang, Guan-Guan Zhao, Jie Sun, Wen Hu, Hong Shan, H. Eric Xu

    G-protein-coupled receptors (GPCRs) transmit cellular signals through both G protein and arrestin pathways and biased signaling offers potential therapeutic advantages through selective activation. Although GPCR–G protein complexes are well characterized, structural understanding of class B GPCR–arrestin interactions remains limited. Here we show the cryo-electron microscopy structure of parathyroid hormone receptor 1 in core engagement with β-arrestin 1, revealing the molecular basis of arrestin coupling. The structure shows a rearrangement in which inward movement of extracellular transmembrane helix 5 (TM5) and extracellular loop 3 (ECL3) drives outward displacement of cytoplasmic TM5, forming a configuration required for arrestin binding. Guided by comparison with the Gs-coupled state, we designed peptide analogs that prevent these TM5/ECL3 conformational changes, producing G-protein-biased agonists that preserve agonist efficacy while reducing arrestin recruitment. In an ovariectomized mouse model, a lead compound shows comparable therapeutic efficacy, providing a framework for structure-guided design of biased therapeutics targeting class B GPCRs.


  • Molecular basis for cross-activation of NPFF2R by a short PrRP-related peptide

    by Xin Li, Shuai Li, Hong Shan, Qing-Ning Yuan, Xin-Heng He, Qian He, Min Zhang, Yang Li, Wen Hu, Kai Wu, et al.

    Prolactin-releasing peptide (PrRP) is an endogenous ligand for the PrRPR, whose activation has been linked to anti-obesity effects. However, PrRP and its analogs also activate the neuropeptide FF receptor 2 (NPFF2R), which is associated with adverse cardiovascular effects. Understanding how PrRP-related peptides differentially engage these two distinct receptors is critical for developing safer, more selective therapeutics. In this study, we present cryo-EM structures of the PrRP analog GUB08248 bound to PrRPR-Gαq and NPFF2R-Gαi at resolutions of 2.45 Å and 2.85 Å, respectively. These structures reveal a conserved ligand recognition mode across both receptors, while highlighting distinct receptor-specific interactions. The NPFF2R-Gαi complex further uncovers key features of receptor activation and G protein coupling. Together, our results offer structural insights that could guide structure-based drug design strategies favoring PrRPR selectivity, thereby advancing the therapeutic potential of the PrRP-PrRPR axis for obesity treatment.

  • Open Access

    Structural insights into nonpeptide antagonist inhibition of somatostatin receptor subtype 5

    by Yang Li, Zhongliang Xing, Wen Hu, Kai Wu, H. Eric Xu, Li-Hua Zhao

    The somatostatin receptor subtype 5 (SSTR5) is a critical pharmacological target involved in neuroendocrine signaling, metabolic regulation, and tumorigenesis. Despite its therapeutic potential, the structural mechanisms underlying SSTR5 inhibition by nonpeptide antagonists remain largely unresolved. In this study, we present high-resolution cryoelectron microscopy structures of human SSTR5 in complex with two selective small-molecule antagonists, antagonist 1 and S5A1, revealing the receptor’s inactive conformation. Both antagonists induce a unique remodeling of extracellular loop 2, which adopts a capping architecture that sterically occludes the orthosteric site, thus preventing agonist access and stabilizing receptor inactivation. Structural analyses and functional experiments elucidate how distinct molecular moieties of the antagonists differentially contribute to inhibitory efficacy, and subtype selectivity. Furthermore, we delineate rational avenues for molecular optimization to enhance therapeutic index and mitigate off-target liabilities. These findings, complementing our previous agonist-bound structures, establish a comprehensive structural foundation for developing improved nonpeptidic SSTR5 antagonists with potential therapeutic applications for type 2 diabetes and related endocrine disorders.


  • Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors

    by Yi-Min Gu, Qing-Ning Yuan, Xin Li, Qian He, H. Eric Xu, Li-Hua Zhao

    The global obesity epidemic and its associated metabolic disorders urgently require more effective therapeutic interventions, particularly multi-pathway targeting therapies. Cagrilintide (Cagri), functioning as a dual amylin receptor (AMYRs) and calcitonin receptor (CTR) agonist (DACRA), demonstrates significant efficacy in obesity treatment, although its structural activation mechanism remains unclear. This study elucidates the non-selective activation mechanism by determining cryo-EM structures of Cagri bound to AMY1R-Gs and CTR-Gs complexes. Cagri adopts similar “bypass” binding modes in both receptors, which is distinct from other existing DACRAs that primarily achieve extended half-life through N-terminal lipid modification. Key molecular features include the F23Cagri residue anchoring the peptide at the receptor transmembrane (TM) bundle level and the micelle, an E14-R17 intramolecular salt bridge enhancing helical stability, and C-terminal P37Cagri interaction with the receptor ECD. These features collectively enable non-specific binding and activation across different receptors. Both structural and functional analyses revealed Cagri’s non-selective activation of Gs signaling pathways through CTR and AMY1R. These findings provide a comprehensive structural framework for developing next-generation anti-obesity drugs based on dual receptor activation mechanisms.